泌尿生殖道感染病原菌分布及药敏状况分析

Analysis on distribution of pathogenic bacteria and drug sensitivity in patients with urogenital tract infection

目的观察泌尿生殖道感染患者病原菌分布及药敏状况。方法选择600例泌尿生殖道感染患者为研究对象,采集男性尿道分泌物、女性宫颈分泌物于无菌环境下进行病原菌培养及药敏试验,观察病原菌分布情况,并分析其耐药性。结果 600例泌尿生殖道感染患者中共分离出1 562株病原菌,包括1 103株支原体和459株细菌,支原体以解脲支原体(Uu)和人型支原体(Mh)为主,分别占33.03%(516/1 562)、14.40%(225/1 562);细菌以肠杆菌科和肠球菌属细菌为主,分别占11.65%(182/1 562)、8.58%(134/1 562)。药敏试验发现,Uu、Mh对交沙霉素、强力霉素、美满霉素的敏感性较高,对红霉素、氧氟沙星的敏感性较低;肠杆菌科细菌对亚胺培南、美洛培南、哌拉西林/他唑巴坦的敏感性较高,对阿莫西林、替卡西林的敏感性较低;肠球菌属细菌对万古霉素、替考拉宁的敏感性较高,对红霉素的敏感性较低。结论泌尿生殖道感染患者以支原体感染为主,同时也存在细菌感染。因此,临床应关注感染患者病原菌敏感性试验结果,合理选择用药。

Objective To observe the distribution of pathogenic bacteria and drug sensitivity of patients with urogenital tract infection.Methods A total of 600 patients with urogenital tract infection were selected as study subjects,and urethral discharge of male patients and cervical secretions of female patients were collected,pathogen culture and drug sensitivity test were conducted in a sterile environment,the distribution of pathogenic bacteria and drug resistance were observed and analyzed.Results A total of 1562 strains of pathogenic bacteria were isolated from 600 patients with urogenital tract infection,including 1103 strains of Mycoplasma and 459 strains.Ureaplasma urealyticum(Uu)and Mycoplasma hominis(Mh)were main Mycoplasma infection,accounting for 33.03%(516/1562)and 14.40%(225/1562),respectively;Enterobacteriaceae and Enterococcus were the main bacteria,accounting for 11.65%(182/1562)and 8.58%(134/1562),respectively.The susceptibilities test showed that Uu and Mh were highly sensitive to josamycin,doxycycline,and minocycline,while their sensitivities to erythromycin and ofloxacin were low.Enterobacteriaceae was highly sensitive to imipenem,meroppenem,piperacillin/tazobactam,while was lowly sensitive to amoxicillin and ticacillin.Enterococcus was highly sensitive to vancomycin and tekoranin,while was lowly sensitive to erythromycin.Conclusion Mycoplasma infection is the main infection source in patients with urogenital tract infection,and bacteria infection is also presented.Therefore,clinical trials should be strengthened the susceptibility results of pathogenic bacteria in infected patients,so as to reasonably select antibacterial drugs.